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 ABSTRACT 
 
Thermodynamic Effects of Phospholamban on Ca-ATPase Kinetics 
 
Patrick L. Apopa 
 
The Ca-ATPase of sarcoplasmic reticulum removes cytosolic calcium to promote muscle 
relaxation.  In the heart, the Ca-ATPase is regulated by phospholamban, which inhibits 
the Ca-ATPase by decreasing Ca-ATPase calcium sensitivity.  However, the kinetic and 
thermodynamic mechanisms of inhibition are not understood.  The purpose of this 
research was to test the hypothesis that phospholamban regulates Ca-ATPase kinetics by 
increasing Ca-ATPase activation energy.  The baculovirus-insect cell expression system 
was used to produce samples containing Ca-ATPase alone or Ca-ATPase with 
phospholamban.  The temperature-dependence of Ca-ATPase activity and catalytic site 
density was measured in the absence and presence of phospholamban at sub-saturating 
calcium and used to calculate the temperature-dependence of Ca-ATPase turnover.  
Arrhenius analyses showed that phospholamban increased Ca-ATPase activation energy 
from 31 ± 3 J/mol (Ca-ATPase only) to 52 ± 5 J/mol (Ca-ATPase + phospholamban).  
The results supported the hypothesis and provided new insight into the mechanism of 
phospholamban inhibition of Ca-ATPase.
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Chapter 1: Introduction 
There is a high prevalence of heart disease worldwide and mortality due to heart 
related ailments is on the rise. There is a need for increased understanding of the etiologic 
mechanisms associated with these varieties of cardiac dysfunction, and this should 
translate to a more targeted therapy. 
The heart tissue is composed of different cell types, namely the smooth muscle 
cells, fibroblasts and cardiac myocytes. The cardiac myocytes are the contractile cells of 
the heart. It is prudent therefore to understand the structural component of the myocyte in 
relation to its function. The myocytes are surrounded by a basement membrane, which is 
composed primarily of type I collagen, the glycoproteins laminin and fibronectin and 
proteoglycans. The basement membrane provides a barrier that influences the exchange 
of macromolecules between the extracellular space and the cell. It also provides an 
interface for cell adhesion and continuity with intracellular matrix. There is also the 
sarcolemma, which consists of the plasma membrane and the basement membrane. The 
sarcolemma is composed of the lipid bilayer, which contains hydrophilic heads and 
hydrophobic tails. This composition allows it to interact with intracellular and 
extracellular environment. The hydrophobic tails however, make the sarcolemma 
impermeable to charged molecules.  The sarcolemma forms two specialized regions of 
the myocyte, the intercalated disc and the transverse tubular system. The intercalated disc 
has a specialized cell-cell junction, which functions as a strong mechanical linkage 
between myocytes yet has low resistance to allow for rapid conduction of action potential 
between myocytes. 
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The transverse tubules, (or T-tubules) are invaginations of the sarcolemma into 
the myocytes, which form a barrier between the intracellular and the extracellular spaces. 
These extensions bring in close apposition the L-type Ca2+ channels and the sarcoplasmic 
reticulum Ca discharge system and this makes the T-tubular system an important 
structural component in excitation-contraction coupling.  
The major component of the sarcolemma is the lipid bilayer. Therefore, as with 
other lipid bilayers, it provides a barrier for diffusion. The sarcolemma contains various 
membrane proteins, which include receptors, pumps and channels. This specialized 
feature of the sarcolemma is essential to the contractile process of the myocyte (Walker 
and Spinale, 1999). The pumps and channels of the myocyte sarcolemma can be best 
reviewed when placed in the context of the phases of action potential represented in 
Figure 1. 
The resting membrane potential or phase 4 of the action potential is maintained 
primarily by the inward K+ rectifier and secondarily influenced by the Na+/K+ adenosine 
triphosphatase (ATPase). During the resting membrane potential, the sarcolemma is only 
permeable to K+, thus it is the K+ equilibrium potential that determines the resting 
membrane potential of the myocyte. The inward K+ rectifier allows for the K+ diffusion 
into the cardiac myocytes. The Na+/K+ ATPase then generates an outward current 
through the extrusion of three Na+ ions for two K+ ions to maintain the resting potential. 
There is also the Na+/ Ca2+ exchanger and the sarcolemmal Ca2+-ATPase, which provide 
the basis for Ca2+ extrusion from the myocyte. The Na+/ Ca2+ exchange is a bidirectional 
channel; with the relative amounts of either ion carried across the membrane determined 
by the concentration o either side of the membrane (Philipson, 1990). 
 3
 
 
 
Figure 1: A schematic of myocyte action potential.  The cardiac action potential 
consists of 5 phases. Phase 0, the upstroke, correspond to rapid depolarization. The 
upstroke is followed by phase 1, a brief early repolarization, phase 2 or plateau, phase 3 
or rapid repolarization and phase 4, which correspond to the resting membrane potential. 
This action potential is the result of sarcolemmal protein interactions that have been 
summarized in the text.
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       During the action potential, the upstroke of phase 0 (Figure 1) is created by the fast 
Na+ channel. In an all or non-mechanism, this upstroke occurs when the membrane 
potential achieves a preset threshold voltage and the Na+ channels rapidly activate 
(<1ms). The channel remains activated for duration of only 2-10ms, thus the name fast 
Na+ channel. This activation allows Na+ to flow into the cell along both electrical and 
chemical concentration gradients. This influx of Na+ through the fast Na+ channel triggers 
the ionic processes responsible for the other phases of the action potential (Walker and 
Spinale, 1999). Rapid inactivation of Na+ channels and slower activation of two outward 
currents are the basis for early repolariztion (phase 1). The positive membrane potential, 
the Cl- concentration gradient, and increased membrane permeability to Cl- allows for the 
entry of Cl- into the cell. A transient efflux of K+ through specific channels occurs along 
the K+ electrochemical gradient. All these three events are responsible for the brief and 
small repolarization of the membrane potential during phase 1 of action potential. 
Phase 2 of the action potential is mainly determined by the influx of Ca2+ through 
the L-type Ca2+ channels (Balke and Shorofsky, 1997). Additionally, there is a 
counterbalancing outward K+ current that flows through the  anomalous K+ rectifier 
(Katz, 1992). These channels are both activated during the upstroke of the action 
potential and reach peak current concurrently during phase 2 of the action potential. 
Phase 3 of the action potential, which is the repolarization phase, is the result of 
increased K+ conductance through the delayed rectifier K+ channel. These channels are 
activated towards the end of phase 2 and they allow K+ ion to flow out of the cell along 
the concentration gradient. At this stage of the action potential, the other inward currents, 
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Na+ and Ca2+ are inactivated, making the delayed rectifying K+ current responsible for 
the restoration of the membrane potential to the resting state. 
The excitation-contraction coupling is the mechanism by which the action 
potential leads to contraction of the myocyte. It is basically achieved through an increase 
in cytosolic Ca2+ levels from nanomolar to micromolar concentrations (Berne and Levy, 
1997). 
Calcium is pivotal to regulation of the rhythmic contraction/relaxation cycle in the 
heart. Ultrastructural evidence indicates that the L-type calcium channels embedded in 
the transverse tubules are functionally and physically associated with the ryanodine 
receptors/ Ca2+ release channels on the sarcoplasmic reticulum (SR) in contractile 
muscle. In cardiac myocytes, communication between the L-type Ca2+channel and 
ryanodine receptor stimulate release of Ca2+ from the SR.  This is known as the Ca2+-
induced Ca2+ release (CICR) mechanism.  This is where the action potential reaches the 
myocyte and a wave of depolarization at the T-tubular system result in the activation of 
the sarcolemmal voltage sensitive Ca2+ channel, also referred to as the dihydropyridine 
receptor (DHPR) and leads to Ca conductance (Mukherjee and Spinale, 1998). This rapid 
but small influx of Ca2+ through the L-type Ca2+ channels causes activation of Ca2+ 
release channels which then release large amounts of Ca2+ into the cytosol (Berrige, 
1997; Bers, 1991).   
 For CICR to produce optimal response, it is postulated that either larger calcium 
releases must inactivate the Ca2+ release channels (Fabiato, 1985), or the released calcium 
must dissipate rapidly from the vicinity of the ryanodine receptor during random and 
calcium-independent close intervals of the release channels (Morad and Cleeman, 1987).  
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The increase in the cytosolic Ca2+ level results in the Ca2+ binding to the Troponin 
complex and following the release of Ca2+ from the sarcoplasmic reticulum, a series of 
interactions occur within the contractile proteins of the sarcomere that serves as the 
fundamental basis of muscle contraction (Berne et al., 1997). The fundamental proteins 
of the contractile apparatus are myosin, actin, tropomyosin and the troponin complex. 
Myosin, the thick filament, is composed of a filamentous tail and a globular head region. 
The myosin head contains the actin binding site and the catalytic site for ATP hydrolysis, 
which drives the muscle contraction. Actin is the major contractile protein found in the 
thin filament. It has two forms, namely the monomeric (G) form and the polymeric (F) 
form, composed of individual G actin monomers. F-actin forms the backbone of the thin 
filament. Each monomer of G-actin within the F-actin has two myosin binding sites. The 
interaction between the myosin globular head and the actin unit in the presence of ATP 
results in crossbridge formation and sarcomere shortening. Tropomyosin is another 
protein found in the thin filament. It lies on either side of actin, thus adding rigidity to the 
thin filament. Tropomyosin influences actin-myosin cross bridge formation by physically 
interdigitating between the actin-myosin cleft (Katz, 1992). The troponin complex, also 
present in the thin filament is composed of three proteins namely troponin T, I, and C. 
Troponin regulates the extent of crossbridge formation and contributes to the structural 
integrity of the sarcomere. Troponin T binds the troponin complex to tropomyosin and 
anchors the complex to the thin filament. Normally, phosphorylated troponin I weakens 
the affinity of troponin C for Ca2+. The binding of Ca2+ to troponin C results in a 
conformational change of the complex, which exposes the actin /myosin binding cleft, 
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promoting subsequent actin-myosin interaction, thus initiating cross bridge formation and 
muscle contraction.  
Muscle relaxation depends upon the reduction of cytosolic calcium levels. This is 
realized mainly by the SR Ca2+ pump which transports Ca2+ back to the sarcoplasmic 
reticulum in an ATP dependent manner. The sarcolemmal Ca2+-ATPase also removes a 
significant portion of Ca2+. Additional Ca2+ binding proteins like calmodulin and 
calsequestrin are also important. The complex formed when calmodulin binds 
intracellular Ca activates the sarcolemmal Ca2+-ATPase to extrude cytosolic Ca2+ (Feher 
et al., 1990; Sheu et al., 1986). Calsequestrin binds Ca within the cardiac SR lumen 
where it is located (Katz et al., 1986; Feher et al., 1990), and is the major Ca2+ reservoir 
between events. 
In the failing hearts, patients exhibit both systolic and diastolic dysfunction. This 
is brought about by, among other things, cell death (microinfarction and scar) (Knowlton 
et al., 1992), dysfunctional cardiac metabolism (inadequate energy supply) (Alpert et al., 
1962), abnormalities in cytoskeleton and contractile proteins (Unverferth and Lee, 1988), 
alteration in myocyte excitation-contraction coupling (Limas et al., 1987), dysfunctional 
myocyte signal transduction (Mitchell et al., 1995) and altered intracellular calcium 
transport and regulation. Of the various mechanisms stated above, intracellular calcium 
transport and regulation is the most dynamic and potentially reversible, thus the most 
treatable. Therefore, understanding the mechanism of calcium transport and its regulation 
is an important step towards finding a solution to heart disease. 
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Ca2+ATPase 
 The sarco(endo)plasmic reticulum Ca2+- ATPases (SERCA) are 110 kDa, P-type 
ATPases that are responsible for the movement of Ca2+ from the cytosol to the lumen of 
the sarcoplasmic reticulum (SR). They are called P-type ATPases because they have an 
aspartate residue, within a DKTG consensus sequence that is phosphorylated by ATP 
during catalysis. The Ca2+ATPase of muscle sarcoplasmic or endoplasmic reticulum 
consist of a single polypeptide chain, unlike other ATPases, which exist as α, β- 
heterodimers Na+/K+ ATPase. The SERCA pumps are coded for by 3 genes, named 
SERCA 1, 2 and 3. SERCA 1 is expressed mainly in fast twitch skeletal muscle. SERCA 
2 consist of two isoforms, SERCA2a which is expressed in slow-twitch, cardiac and 
smooth muscle while SERCA2b has non-muscle distribution, including the brain. 
SERCA3 has a wide tissue distribution.  
The amino acid sequences of most P-type ATPases have been known for some 
time and extensive mutational studies have been carried out to identify amino acids that 
are critical for ion transport. As shown in Figure 2 below, the Ca2+- ATPase consists of 
three globular cytoplasmic domains connected by  helical stalk segments to ten 
transmembrane α-helices (M1-M10). The first domain is a 125-residue loop connected to 
stalk regions S2 and S3, known as the activator domain. Next there is the phosphorylation 
domain, which is connected to stalk regions S4 and S5 and contains Asp-351, which 
becomes phosphorylated by ATP. Finally there is the nucleotide-binding domain (N 
domain) that is connected directly to the P domain. 
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Figure 2: Secondary structure of the Ca2+-ATPase based on the crystal structure by 
Toyoshima et al (1998).  The three cytoplasmic domains A (activation), P 
(phosphorylation) and N (nucleotide binding) are connected to the transmembrane α-
helical stalks (numbered 2-5 in accordance with the transmembrane α-helix to which they 
are attached). The N domain forms an insert into the P domain. The location of the 
conserved phosphorylation motif is shown. 
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The crystal structure of the SERCA1 Ca2+- ATPase was reported in 2000. The ten 
transmembrane α-helices, three cytoplasmic globular domains and the small loops on 
lumenal side were well resolved in structure (Figure 3). All the 994 amino acids in the 
crystal structure shown above were identified in the electron-density maps. 
 The structure of the Ca2+-ATPase crystallized in the presence of Ca2+ and the ATP 
analogue  23-0-(2,4,6-trinitrophenyl)-adenosine monophosphate (TNP-AMP) shows 
TNP-AMP binding to the surface of the N domain, more than 25Ǻ away from Asp 351 
(Figure 3) (20) TNP-AMP is presumed to bind to the nucleotide binding site, since 
binding of analogues of TNP-AMP is competitive with binding of ATP. Because the 
adenosine moiety is known to bind around Lsy-515, Lys-492 and Phe-487 in the N 
domain, and because the phosphorylation site (Asp-351) on the P domain is distant by 
about 25 Ǻ in the crystal structure of the Ca2+ bound (E1) state (Toyoshima et al, 2000), 
very large motion of domain closure is necessary for the γ-phosphate of bound ATP to 
reach the phosphorylation site. This was recently confirmed by Toyoshima and coworker, 
who also showed the close interaction of the N, P and A domains in the crystal structure 
of the Ca2+ free Ca2+-ATPase. 
 
Mechanism of the Ca2+-ATPase 
 The mechanism of the Ca2+-ATPase is usually discussed in terms of E1-E2 model 
developed from the Post-Albers scheme for the (Na+, K+)- ATPase, as shown in Scheme 
1. The model proposes that the Ca2+-ATPase can exist in two distinct forms, E1 and E2. 
The E1 conformation contains two high affinity binding sites for Ca2+ that are exposed to 
the cytoplasm, whereas in the E2 conformation these two sites are transformed to low  
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Figure 3: Crystal structure of Ca2+- ATPase 
In the figure, the cylinders represent α-helices and arrows β-strand. The cylinders are not 
used for one-turn helices. The color changes gradually from N-terminal (blue) to C-
terminal (red). The three cytoplasmic domains are labeled A, N and P.  The 
transmembrane helices (M1-M10) and those in domains A and P are numbered. The 
orientation of the model shown above is such that Helix M5 is parallel to the plane of the 
paper. The model in the right panel is rotated by 50û around M5, which is 60Å long and 
serves as a scale. Several key residues are shown in ball-and-stick, and 23-0-(2,4,6-
trinitrophenyl)-Adenosinemonophosphate (TNP-AMP), which is a non-hydrolysable 
analog of ATP is shown.  D351 is the residue of phosphorylation. Two purple spheres 
represent Ca2+ in the transmembrane binding site. The binding sites for phospholamban 
(PLN) and thapsigargin (TG) are marked. Also marked are the major digestion sites for 
Trypsin (T1 and T2) and proteinase K (PrtK).  These digestion sites are important 
because they have been used to show changes in the cytoplasmic domain, which results 
in changes of accessibility of the enzyme to the cleavage sites. Reprinted with permission 
from Nature (Toyoshima, C., Nakasako, M., Nomura, H., Ogawa, H. 2000. Crystal 
structure of the calcium pump of sarcoplasmic reticulum at 2.6 Ǻ resolution.  Nature 405: 
647-654), www.nature.com/nature.    
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      MgATP                               ADP
E1•Ca2              E1•Ca2•ATP             E1P(Ca2)
                  1                               2                              
     7                                                            3
           6                   5                4
E2               E2•Pi           E2P             E2P(Ca2)
     Mg2+, Pi               H2O     2Ca2+ in   
2Ca2+ out
 
 
Scheme 1: E1/E2 Scheme for the CaATPase. Either ATP or Ca2+ can bind first to the 
E1 conformation of the CaATPase. A series of conformational changes leads to the 
intermidiate E1·Ca2·ATP which undergoes phosphorylation to give E1P(Ca2 ), which then 
undergoes further conformational changes to give E2P(Ca2 ). This loses Ca2+ into the 
lumen and can be dephosphorylated to form E2, which can return to E1. 
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affinity sites exposed to the lumen of the SR. This is referred to as the alternating site 
model. Following the binding of MgATP to the Ca2+-bound form of the ATPase (Step 1), 
the ATPase is phosphorylated at D351 forming E1P (Step 2), which undergoes a change 
in conformation to E2PCa2 (Step 3), a state in which the two Ca2+ binding sites are of low 
affinity and inwardly facing. Following the loss of Ca2+ to the lumen of the SR (Step 4), 
the ATPase is dephosphorylated (Steps 5 and 6) and recycled to E1, which binds Ca2+ 
 The phosphorylation and dephosphorylation events of the enzyme are reversible. 
The phosphorylated enzyme can react with ADP in the presence of Ca2+ to regenerate 
ATP. Also, incubation of the Ca2+ATPase with phosphate (Pi) in the absence of 
cytoplasmic calcium, lead to phosphorylation of the ATPase to form E2P (Lacapere et 
al., 1981). 
 
Phosphorylation of the ATPase 
It has been shown using chemical labeling that the adenine and γ-phosphate 
moieties of ATP bind to separate domains on the ATPase, the N and P domains 
respectively. Analogues of ATP with reactive groups on the nucleotide ring invariably 
label residues in the N domain. ATP analogues block phosphorylation by ATP, but they 
do not affect smaller pseudo substrates like acetyl phosphate or Pi (Stokes and Green, 
2000). However, if the reactive group is close to the γ-phosphate of ATP, then the 
enzyme residues labeled are in the P domain and neither ATP nor Pi can phosphorylate 
the modified ATPase. 
The catalytically active E1Ca2ATP conformation (Figure 3) can be produced by 
a pathway in which either Ca2+ or ATP binds first to the ATPase (Reinstein and Jencks, 
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1993). However, the activated state can only be reached following the binding of both 
ATP and Ca2+.    Binding of MgATP and activation of the enzyme is relatively slow in 
either pathway. This is because ATP binding is not simply an encounter process but, 
rather, involves a conformational change on the ATPase, triggered by ATP binding to the 
ATPase (Reinstein and Jencks, 1993).  
 
Phospholamban (PLB) 
Phospholamban is a small (52 residue) membrane-bound protein that modulates 
the activity of the Ca2+ -ATPase in cardiac muscle SR. 
Following the discovery of phospholamban, early work focused on its apparent 
role in regulation of calcium transport across the sarcoplasmic reticulum and sketching its 
complex protein structure. Other recent work has focused on the role of phospholamban 
in the regulation of myocardial function by catecholamines (Davis et al., 1990) and the 
role of phospholamban in skeletal and smooth muscle (Lompre et al., 1994). 
Initially, phospholamban was implicated in the regulation of calcium transport 
across the cardiac SR by the correlation of cAMP-induced stimulation of calcium 
transport by the CaATPase, with the predominant phosphorylation of PLB by cAMP-
dependent protein kinase (Kirchberger et al, 1974). Because of its known role then as the 
principle substrate of cAMP-dependent protein kinase in cardiac SR vesicles, Tada et al  
(1975) named the protein phospholamban, meaning phosphate receptor. The level of 
calcium transport stimulated by the cAMP-dependent mechanism was commensurate 
with the degree of phosphorylation of PLB (Tada and Katz, 1982). Phospholamban was 
also found to be the principle substrate of an endogenous myocardial 
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calcium/calmodulin-dependent protein kinase. The phosphorylation of PLB by the 
cAMP-dependent protein kinase occur independently and additively (Imagawa et al, 
1986), as does concomitant stimulation of calcium transport and ATPase activity 
(Kranias, 1985) 
Structurally, PLB consists of a hydrophilic N-terminal domain (Met1 to Asn 30) 
linked to the hydrophobic C-terminal domain (Leu31 to Leu 52), which is likely to be a 
transmembrane α-helix . PLB when unphosphorylated binds to the ATPase and inhibits 
it. Phosphorylation of PLB by Ca2+ / Calmodulin-dependent or cAMP-dependent protein 
kinase results in full ATPase activity, presumably as a result of uncoupling of PLB from 
the ATPase. The binding of PLB to the Ca2+-ATPase in cardiac SR reduces the apparent 
affinity of the ATPase for Ca2+. This has been determined from plots of Ca2+ uptake rate 
as a function of Ca2+ concentration. Other studies suggest that PLB controls Ca2+ATPase 
activity by decreasing by two fold the rate of phosphoenzyme decomposition. Froelich 
and Taylor (1975,1976) have shown in kinetic studies that Ca2+ATPase phosphoenzyme 
decomposition is a two-step process in which E2P is first hydrolyzed to E2.Pi followed 
by the release of Pi from the enzyme forming an E2 intermediate. PLB however, does not 
cause a decrease in ATPase activity at saturating concentrations of calcium.  
PLB forms homopentamers that are stable in SDS-PAGE (Wegener and Jones, 
1984). Spectroscopic analysis has verified that PLB is primarily oligomeric in lipid 
bilayer (Cornea et al., 1997). Simmerman et al (1996) showed by the use of site directed 
mutagenesis, the regions in PLB that are essential for pentameric stability. They also 
proposed that PLB pentamer is a left-handed coiled-coil, which is stabilized specifically 
by interactions between leucine residues 37, 44 and 51 and isoleucines 40 and 47. Autry 
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and Jones (1997) have shown that it is monomeric phospholamban that binds to and 
regulate the Ca2+-ATPase 
  Phospholamban has been purified (Inui et al., 1985; Jones et al., 1985), and its 
primary structure has been determined by cDNA cloning and sequencing (Fujii et al., 
1987). It consists of five identical monomers (Wegener and Jones, 1984; Fujii et al., 
1986), each of which contains two distinct domains, the hydrophilic N-terminal domain 
(domain I) and the hydrophobic C- terminal domain (domain II) (Fujii et al., 1986; 
Simmerman et al., 1986; Tada et al., 1988). The first 20 residues from the N-terminal 
(domain IA) are predicted to form an α-helical structure containing serine 16 and 
threonine 17  phosphorylated  by cAMP- and calmodulin-dependent protein kinases, 
respectively. The next 10 residues are less structured (domain IB). The last 22 residues 
form a hydrophobic transmembrane domain (domain 11). Recently, a direct protein- 
protein interaction has been demonstrated between phospholamban and Ca2+-ATPase, 
which is diminished by phosphorylation of phospholamban (James et al., 1989).  
The physiological role of phospholamban in cardiac health and disease has been 
the source of much speculation. Phospholamban clearly is a mediator in the regulation of 
myocardial function by catecholamines through the cyclic AMP cascade. This is 
consistent with the distribution of phospholamban in slow-twitch skeletal muscle as well 
as cardiac muscle which both exhibit cAMP-dependent stimulation of cardiac transport. 
Phospholamban however, has not been identified in fast-twitch skeletal muscle, which 
lack this response pathway (Jorgensen and Jones, 1986; Kimura et al., 1996). The 
physiological role of phospholamban has been demonstrated by recent work with 
cardiomyocytes and phospholamban knockout mice, and it was found that ablation of 
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phospholamban greatly augments the intracellular Ca2+ transient and myocardial 
contractility and at the same time attenuates the cardiac response to β-adrenergic agents 
such as isoproterenol. Likewise, the overexpression of phospholamban or the expression 
of non-phosphorylatable phospholamban in transgenic mice lead to a variety of cardiac 
disease states, including cardiac hypertrophy and heart failure (Brittsan and Kranias, 
2000). 
 
Overview of Thesis Research 
Despite considerable progress toward understanding the functional interaction of 
phospholamban with the Ca-ATPase, fundamental questions remain concerning the 
kinetic basis by which phospholamban inhibits the Ca-ATPase.  The primary functional 
effect of phospholamban on the Ca-ATPase is to decrease the apparent Ca2+ affinity of 
the enzyme (see Figure 1, below).  There have been many kinetics studies on the effects 
of phospholamban on the partial reactions of the Ca-ATPase cycle (Tada et al., 1975, 
1979, 1980; Jones et al., 1978; Kranias et al., 1980; Sumida et al., 1980; Cantilina et al., 
1993; Antipenko et al., 1997, 1999; Mahaney et al., 2000) designed to elucidate this 
effect.  However, these studies have failed to provide a definitive mechanism by which 
phospholamban decreases the apparent Ca2+ affinity of the Ca-ATPase.   
The most widely accepted view of the mechanistic basis for Ca-ATPase inhibition 
by phospholamban was reported by Cantilina et al. (1993), who proposed that 
phospholamban decreases by ten fold the rate of a Ca2+-dependent conformational change 
that activates the Ca-ATPase for ATP-dependent phosphoenzyme formation.  In so 
doing, phospholamban makes the Ca-ATPase less sensitive to Ca2+, giving the 
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appearance of a change in Ca2+ affinity.  However, the effect of phospholamban on the 
Ca2+-dependent activation of the Ca-ATPase has not been tested quantitatively.  To do 
this, one must first determine whether phospholamban affects the net activation energy of 
the Ca-ATPase during steady-state enzyme cycling.  In light of a positive result, one can 
focus specifically on the activation energy of the Ca2+-dependent conformational 
transition that precedes Ca-ATPase phosphorylation by ATP. 
The goal of this thesis research was to test the hypothesis that phospholamban 
increases the activation energy for steady-state enzyme cycling.  To test this hypothesis, 
we have studied the effect of phospholamban on the temperature dependence of Ca-
ATPase steady-state activity and phosphoenzyme levels.  These parameters were used to 
calculate the enzyme turnover number as a function of temperature, in order to determine 
the activation energy for steady-state enzyme cycling.  For these studies, we have 
employed the baculovirus-insect cell expression system to produce samples containing 
the cardiac Ca-ATPase expressed in the absence (control) and presence of co-expressed 
phospholamban.  An advantage of using this system was that it produced sufficient 
quantities of sample for detailed kinetics studies, while at the same time allowing us to 
examine the Ca-ATPase co-expressed alone versus Ca-ATPase co-expressed with 
phospholamban.  The effect of phospholamban on Ca-ATPase turnover was explored 
further by using anti-phospholamban monoclonal antibody to uncouple phospholamban 
from the Ca-ATPase.  In particular, we have pursued the following specific aims: 
 
Aim 1: Determine the influence of phospholamban on the temperature-dependence 
of Ca-ATPase steady-state activity.  For these studies, we utilized an NADH-based 
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enzyme-coupled assay in a temperature-controlled UV-VIS spectrophotometer to 
determine if Ca-ATPase steady-state activity is affected by phospholamban. 
 
Aim 2: Determine the effect of phospholamban on Ca-ATPase pre-steady state 
phosphorylation kinetics.  For these studies, we utilized 32P-ATP to measure steady-
state Ca-ATPase phosphorylation levels, as affected by phospholamban. 
 
Aim 3: Combine the results of Aims 1 and 2 to determine the effect of 
phospholamban on Ca-ATPase activation energy.  Ca-ATPase velocity (nmol ATP 
split / mg protein / sec) divided by the phosphoenzyme level (nmol EP / mg protein) 
provided the Ca-ATPase turnover number, kcat, as a function of temperature.  An 
Arrhenius plot of kcat versus 1 / T provided the activation energy for the Ca-ATPase in 
the absence and presence of phospholamban. 
 
The results of these studies indicated that phospholamban increased the activation 
energy for steady-state Ca-ATPase activity.  Based on this positive result, a more detailed 
analysis of the activation energy of individual steps in the Ca-ATPase cycle is warranted.  
The results of this study, and the studies that will follow this project, should provide new 
insights into the mechanisms of catalysis and regulation of calcium transport in cardiac 
muscle SR, which is a critical step toward understanding cardiac performance and 
malfunction. 
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Chapter 2: Methods 
 
Reagents and Solutions.   
125I-Protein A and [γ-32P]ATP were obtained from ICN.  Other reagents were 
obtained either from Sigma or Fisher Scientific and were of the highest purity available.  
The antibodies used in this study were a gift from Dr. Larry Jones, Indiana University 
School of Medicine. 
 
Protein Expression and Isolation. 
  Recombinant baculoviruses containing cDNA inserts for either canine cardiac 
Ca-ATPase (SERCA2a) or canine phospholamban were prepared by Jamie Huffman in 
our laboratory using the Baculogold Baculovirus Expression Kit from PharMingen.  Wild 
type canine SERCA2a and wild type canine phospholamban were expressed in High-Five 
insect cells grown in suspension (1.5-2.0 x 106 cells/ml) at 27oC in serum free medium 
(Invitrogen).  Microsomes were isolated from insect cells harvested 48 hours after 
infection with baculoviruses.  For expression of Ca-ATPase alone, a multiplicity of 
infection (MOI) of 10 (viruses/cell) was used.  For co-expression of Ca-ATPase with 
phospholamban, a MOI of 15 was used for SERCA2a and 5 for phospholamban (WT).  
Virus-infected High-Five cells in 600 ml suspension (1 x 109cells) were sedimented and 
washed twice with ice cold 1x PBS, by centrifuging for 10 minutes at 1500 rpm and 25oC 
in an IEC GP8R refrigerated centrifuge.  The washed cells were resuspended in 60 ml of 
ice cold 10 mM NaHCO3 and 0.2 mM CaCl2, followed by the addition of 60 ml of ice 
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cold 500 mM Sucrose, 300 mM KCl, 6 mM MgCl2, and 60 mM histidine.  Both buffers 
contained 10 µg/ml aprotinin, 2 µg/ml leupeptin, 1 µg/ml pepstatin A, and 0.1mM 
pefabloc.  The cells were transferred to a cold room (4oC) and homogenized for 90 
seconds with a Brinkman polytron (full speed) and placed back on ice.  The homogenate 
was then centrifuged for 20 minutes at 3000 rpm and 4oC in a Sorvall SS-34 rotor.  The 
supernatant was collected, and 30 ml of 3 M KCl was added to it and it was centrifuged 
for 20 minutes at 9000 rpm and 4oC in a Sorvall SS-34 rotor.  The supernatant was 
collected and the final High-five insect cell microsomes were pelleted by centrifugation 
for 38 minutes at 26000 rpm and 4oC in a Beckman Ti-45 rotor.  Pellets were 
resuspended in 5 ml of buffer containing 250 mM sucrose, 30 mM histidine (pH 7.4) and 
stored in small aliquots at 50oC.  Protein concentrations were determined by the method 
of Lowry et al. (1951), using BSA as a standard. 
 
Electrophoresis and Immunoblotting 
  Prior to electrophoresis, samples were solubilized at 37oC for 5 minutes in a 
dissociation medium that consisted of 62.5 mM Tris (pH 6.8), 5% glycerol, 5% sodium 
dodecyl sulfate (SDS), 40 mM dithiothreitol, and 0.0025% bromophenol blue.  SDS-
PAGE gel electrophoresis was conducted by the method of Porzio and Pearson (1977), 
using 8% polyacrylamide (BioRad Mini-Protean II system).  Kaleidoscope prestained 
molecular weight markers (BioRad) were used as standards.  Gels were stained using 
gelcode blue stain reagent (Pierce), or proteins were transferred (BioRad Mini-Trans blot 
system) to nitrocellulose (SERCA2a blots) or PVDF (PLB blots) membranes (BioRad) 
for immunoblotting.  The transfer protocol was carried out according to instructions 
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provided by the manufacturer, with the exception that methanol was omitted from the 
transfer buffer.  Mahaney et al. (2000) reported that methanol in the transfer medium 
decreased SERCA2a and PLB protein transfer.  The nitrocellulose membranes were 
probed with an anti-SERCA2a monoclonal antibody 2A7-A1 for detection of SERCA2a.  
The PVDF membranes were probed with anti-phospholamban monoclonal antibody 
2D12 for detection of phospholamban (Movsesian et al., 1994).  Antibody binding was 
visualized by using [125I]  protein A and quantitated using Molecular Dynamics 
Phosphoimager SI.  Cardiac SR was used as a standard since it is known to contain 36% 
SERCA2a by weight and 2% PLB by weight, based on quantitative immunoblots using 
purified Ca-ATPase and phospholamban as standards (Waggoner and Mahaney, 
unpublished results).  Typically, our insect cell microsomes contained about 12-15% 
SERCA2a and 1  1.5% phospholamban per total protein by weight.  Converting to 
moles of SERCA2a (Mr = 110,000 g/mol) and phospholamban (Mr = 6,080 g/mol) per 
mg of microsomal protein, these results indicated a molar ratio of 1:2 SERCA2a to PLB, 
similar to that found in native cardiac SR (Mahaney et al., 2000). 
Ca-ATPase Activity Assays. 
    [Ca2+]-dependent ATPase activity of SERCA2a in the High-Five insect cell 
microsomes was measured by two different methods.  The [Ca2+]-dependence of Ca-
ATPase activity was measured colorimetrically at 37oC, using a malachite green-
ammonium molybdate assay (Lanzetta et al., 1979; Mahaney et al., 1995).  SERCA2a 
incubation tubes contained 0.05 mg microsomal protein per ml protein in 50 mM 3-[N-
morpholino]propanesulfonic acid (MOPS) (pH 7.0), 3 mM MgCl2, 100 mM KCl, 1 mM 
EGTA, and 0-1.0 mM CaCl2 to give the desired ionized [Ca2+], as previously determined 
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(Autry and Jones, 1997).  To start the ATPase reaction, 5 mM MgATP was added to the 
incubation tube.  After 10 minutes of reaction at 37oC, a 50 µl aliquot of the incubation 
mix was transferred into an assay tube containing 1.6 ml malachite green-ammonium 
molybdate reagent at room temperature.   After 30 seconds the reaction was quenched by 
the addition of 200 µl of 34% sodium citrate into the assay tube.  For the determination of 
phosphate, a standard curve was constructed using aliquots from a 0.4 mM phosphate 
standard solution, which was assayed in a similar fashion as above.  After 30 minutes of 
color development, the absorbance was measured at 660 nm.  [Ca2+]-dependent ATPase 
activity data were fit by the Hill equation using the program KFIT written by N. C. 
Millar: 
 
])[(
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=  
 
where v is the enzyme velocity at any given [Ca2+], Vmax is the maximum velocity at 
saturating [Ca2+], n is the Hill coefficient, K is the [Ca2+] required for half-maximal 
velocity, and [Ca2+] is the ionized Ca2+ level for each particular assay.  The best fits of the 
data were chosen on the basis of optimization of the determination coefficient, R2, and/or 
minimization of the sum-of-squares error, Π2.   
  For the Arrhenius analyses, Ca-ATPase activity of the microsomal samples was 
measured spectrophotometrically with a continuous ATPase assay using an ATP-
regenerating system (Madden et al., 1979).  Assays were performed in 1 ml of buffer 
containing 50 mM MOPS (pH 7.0), 3 mM MgCl2, 100 mM KCl, 1 mM EGTA, and 0.5 
mM CaCl2, which provided a [Ca2+]free of 0.270 nM, as previously determined (Autry and 
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Jones, 1997).   In addition, the assay cuvettes contained 0.2 mM phosphoenolpyruvate, 0.2 
mM NADH, 8 units pyruvate kinase, 20 units lactate dehydrogenase, which served as an 
ATP regenerating system and provided a means to monitor the progress of the assay.  For 
each assay, 50 µg SR protein was added to the assay cuvette pre-equilibrated at the desired 
experimental temperature and incubated for 5 minutes.  To start the assay, 5 mM MgATP 
was added to the cuvette, and the rate of change of absorbance of NADH at 340 nm was 
recorded to estimate the rate of ATP hydrolysis.   
  For each activity assay, the microsomal samples were permeabilized with the Ca2+ 
ionophore (20 µg per mg total protein) prior to the start of the assay to allow Ca-ATPase 
activity to be measured in the absence of a Ca2+ gradient.  To test the effect of 
phospholamban on Ca-ATPase activity, SERCA2a + PLB samples were incubated for 20 
minutes without or with affinity purified anti-phospholamban monoclonal antibody 2D12 
(courtesy L. Jones), at an antibody-to-protein weight ratio of 1:1 (Autry and Jones, 1997). 
 
Ca-ATPase Phosphoenzyme Levels. 
 Ca-ATPase phosphoenzyme formation experiments were carried out at the 
indicated temperatures using a circulating water bath to control the reaction temperature 
to within ±1oC.  Prior to phosphoenzyme formation, the microsomal samples were 
permeablized by the addition of calcium ionophore A23187 (20 µg / mg protein).  Next, 
0.25 ml of a solution containing 0.2 mg microsomes/ml in 50 mM MOPS (pH 7.0), 3 mM 
MgCl2, 100 mM KCl, 1 mM EGTA and 0.5 mM CaCl2, which provided a [Ca2+]free of 
0.270 nM, as described above, was placed in a 7 ml glass scintillation vial (VWR) and set 
in the water bath.  To initiate phosphoenzyme formation, 0.25 ml of a solution containing 
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50 mM MOPS (pH 7.0), 3 mM MgCl2, 100 mM KCl, 1 mM EGTA, 0.5 mM CaCl2, and 
20 µM [γ-32P]ATP (20,000 cpm/nmol) was rapidly added (less than 1 sec) to the 
microsome-containing vial with vigorous vortexing.  The final conditions following 
mixing were 0.1 mg/ml microsomes, 10 µM [γ-32P]ATP, 50 mM MOPS (pH 7.0), 3 mM 
MgCl2, 100 mM KCl, 1 mM EGTA, and 0.5 mM CaCl2 ([Ca2+]free = 270 nM).  The 
reaction was allowed to proceed for 15 sec before quenching by the rapid addition of 0.5 
ml of ice-cold 9% perchloric acid + 6 mM H3PO4, followed by vigorous vortexing.  After 
quenching, the reaction tubes were placed on ice.  Blank tubes were prepared by first 
adding 0.5 ml of quench solution to the 0.25 ml microsome-containing solution, 
vortexing vigorously, then adding 0.25 ml of the ATP-containing solution.  A 25 µl 
aliquot of 10 mg/ml bovine serum albumin was added to each quenched sample to act as 
carrier protein during the processing of the sample vials.  The quenched samples were 
pelleted by centrifugation for 10 min at 3000 x g, 4 degrees C in an IEC GP8R refrigerated 
centrifuge, and then washed three times by similar centrifugation using an ice-cold 
solution of 5% trichloroacetic acid, 6% polyphosphoric acid, 4 mM H3PO4, and 5 mM 
non-radioactive ATP.  Pellet recovery following washing was greater than 95%, 
determined by protein assay.  The final pellets were dissolved in 5 ml 1 N NaOH and the 
32P-phosphoenzyme was assayed by counting the Cerenkov radiation.  
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Chapter 3: Results 
 
Protein Expression, Characterization and Assay.   
For this study, canine cardiac Ca-ATPase (the SERCA2a isoform) and canine 
phospholamban were expressed in High Five insect cells using recombinant 
baculoviruses (Autry and Jones, 1997) and isolated as High Five insect cell microsomes.  
The Ca2+-ATPase was expressed either alone (Ca2+-ATPase only) or co-expressed with 
wild-type phospholamban (WT-PLB).  The amount of Ca2+-ATPase and phospholamban 
in the insect cell microsome samples was determined by immunoblotting (Figure 4), 
using the Ca2+-ATPase and phospholamban in native cardiac SR vesicles as standards.  
Waggoner and Mahaney (unpublished results) have used quantitative immunoblotting 
techniques to determine the Ca-ATPase and phospholamban content of the cardiac SR 
vesicles, which are 36% and 2% by weight total protein, respectively.  Based on 
phosphorimage analysis of the immunoblot shown in Figure 4, our insect cell 
microsomes contained about 15% Ca-ATPase and 1.5% phospholamban per total protein 
by weight.  Converting to moles of SERCA2a (Mr = 110,000 g/mol) and phospholamban 
(Mr = 6,080 g/mol) per mg of microsomal protein, these results indicated a molar ratio of 
1:2 Ca-ATPase to PLB, similar to that found in native cardiac SR (Waggoner and 
Mahaney, unpublished results). 
The ATPase activity of the expressed Ca-ATPase and the functional coupling 
between Ca-ATPase and phospholamban in the Sf21 cell microsome samples was 
assayed at 37oC at a series of [Ca2+]free in the presence and absence of anti-
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phospholamban monoclonal antibody 2D12, which reverses the inhibitory interaction 
between phospholamban and Ca-ATPase (Briggs et al., 1992; Sham et al., 1991).  Each  
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Figure 4: SDS-PAGE and immunoblot of Ca-ATPase and phospholamban in 
cardiac SR vesicles and High Five insect cell microsomes.  Left: Coomassie blue-
stained SDS gel (10 µg protein per lane) showing cardiac SR vesicles (lane 2), insect cell 
microsomes containing SERCA2a alone (lane 3) or SERCA2a + phospholamban (lane 4)  
Right: corresponding immunoblot of the SDS gel (left) showing cardiac SR vesicles (lane 
5), insect cell microsomes containing SERCA2a alone (lane 6) or SERCA2a + 
phospholamban (lane 7).  PLBpentamer denotes pentameric phospholamban and PLBmonomer 
denotes monomeric phospholamban.  The blots utilized SERCA2a antibody 2A7-A1 
(top) or phospholamban antibody 2D12 (bottom), and were developed with 125I-protein 
A.  The immunoblots were quantified by PhosphorImage analysis.  The cardiac SR 
sample was included as a means to estimate the amount of SERCA2a in the expressed 
samples.  Given that cardiac SR contains 30% SERCA2a and 1.5% phospholamban by 
weight, the two expressed samples contained approximately 14% SERCA2a and 0.7% 
phospholamban by weight by comparison.   
 31
expressed Ca-ATPase sample displayed the usual sigmoidal [Ca2+]-dependence, and the 
maximum steady-state activity (Vmax) of the various samples was similar (approximately 
0.4  0.5 µmol/mg total protein/min) when measured at saturating ionized [Ca2+] (Figure 
5).  Treatment of the expressed samples with monoclonal antibody produced no effect on 
the maximal activity of the sample.  Lack of effect of the monoclonal antibody on the Ca-
ATPase Vmax in cardiac SR vesicles and Ca-ATPase expressed in insect cells is well 
known (Autry and Jones, 1997; Mahaney et al., 2000).  
Ca-ATPase expressed without phospholamban had a high apparent Ca2+ affinity 
(Kca = 200 nM), which was unaffected by treatment of the sample with phospholamban 
monoclonal antibody. When coexpressed with wild-type phospholamban, the Ca-ATPase 
activity curve was shifted to the right relative to that of Ca-ATPase expressed alone, 
resulting in an increase in KCa to 420 nM.   Treatment with anti-phospholamban antibody 
2D12 shifted the Ca2+ activation curve to the left, resulting in a decreased KCa value 
similar to that obtained for Ca-ATPase in the absence of phospholamban.  The results 
show that phospholamban was functionally coupled to Ca-ATPase in the expressed 
samples. 
 
Effect of Phospholamban on the Temperature-dependence of Ca-ATPase Activity.   
To determine the effect of phospholamban on Ca-ATPase activation energy, we 
measured Ca-ATPase activity and phosphoenzyme (EP) levels at a series of temperatures 
between 5oC and 40oC using insect cell microsomes containing Ca-ATPase expressed 
alone (Ca-ATPase only) and in the presence of phospholamban (Ca-ATPase + PLB).  
The effect of phospholamban on Ca-ATPase activation energy was explored further using  
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Figure 5:  Effect of phospholamban on Ca-ATPase activity at 37oC. Ca-ATPase 
activity was measured colorimetically as described in Chapter 2 (Methods), using Hive 
Five insect cell microsomes containing Ca-ATPase expressed alone (Ca-ATPase only, 
open squares, top panel) or Ca-ATPase coexpressed with phospholamban (Ca-ATPase + 
PLB, filled symbols, bottom panel).  The Ca-ATPase samples exhibited a sigmoidal 
dependence on [Ca2+], which was characterized in terms of maximum activity (Vmax) 
and the [Ca2+] required for half maximal activity (denoted KCa).  The K0.5 for Ca-ATPase 
in the presence of phospholamban (filled squares, bottom panel) was approximately 420 
nM, compared to 200 nM for Ca-ATPase alone (empty squares, top panel) or 220 nM for 
Ca-ATPase + phospholamban treated with a monoclonal antibody to uncouple 
phospholamban from the Ca-ATPase (filled circles, bottom panel).  Phospholamban had 
no effect on Vmax for the Ca-ATPase + phospholamban sample.  The results confirm that 
phospholamban inhibits Ca-ATPase by decreasing the Ca2+ sensitivity of the enzyme. 
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an anti-phospholamban monoclonal antibody to uncouple phospholamban from the Ca-
ATPase.  These measurements were conducted at an ionized Ca2+ level of 270 nM, which 
is near the K0.5 value for the Ca-ATPase in the absence and presence of phospholamban 
(Figure 5).   
 As shown in Figure 6, the Ca-ATPase activity of the microsomal samples 
increased with increasing temperature.  The temperature dependence was similar for 
samples containing Ca-ATPase expressed alone (Figure 6, top) or Ca-ATPase 
coexpressed with phospholamban (Figure 6, bottom).  At higher temperatures (25-40oC), 
phospholamban decreased Ca-ATPase activity by about 20% relative to samples treated 
with 2D12 to uncouple phospholamban from the Ca-ATPase.  At lower temperatures (5-
20oC), however, there was no significant difference between untreated and antibody-
treated samples.  The activity of the antibody-treated Ca-ATPase + phospholamban 
sample was similar to that of the Ca-ATPase only sample at each temperature, ensuring 
that the antibody successfully uncoupled phospholamban from the Ca-ATPase at all 
temperatures studied. 
 
Effect of Phospholamban on the Temperature-dependence of Ca-ATPase EP 
formation.   
During the Ca-ATPase reaction cycle, the enzyme is phosphorylated by ATP, 
which drives Ca2+ translocation.  Using radio labeled ATP, one can determine the amount 
of phosphorylated Ca-ATPase during steady state enzyme cycling (Methods).  In effect, 
the EP level provides information about the catalytic site density of the enzyme, since the 
fraction of the enzymes phosphorylated during steady-state cycling gives rise to product  
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Figure 6: Effect of phospholamban on the temperature dependence of Ca-ATPase 
activity.  Ca-ATPase activity was measured at [Ca2+]free = 270 nM at the indicated 
temperatures with a coupled enzyme assay as described in Chapter 2 (Methods), using 
Hive Five insect cell microsomes containing Ca-ATPase only or Ca-ATPase + 
phospholamban (Ca-ATPase + PLB).  The [Ca2+]free was selected to be near the K0.5 value 
for both sample types, where phospholamban has significant effects on Ca-ATPase 
activity (Figure 2).  This experiment was carried out using different (and more active) 
sample preparations than those shown in Figure 2, which is reflected in differences in the 
37 oC activities between the two figures.  The symbols and sample conditions correspond 
to those defined in Figure 5. 
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release and enzyme turnover.  Therefore, the steady-state phosphoenzyme (EP) level of 
each microsomal Ca-ATPase sample was measured as a function of temperature at 270 
nM ionized Ca2+ using  [γ-32P]ATP.  Because temperature was not expected to affect the 
catalytic site density of the Ca-ATPase samples (Mahaney et al., 1995), we focused our 
measurements on three temperatures, 5oC, 20oC and 40oC.  As expected, a similar value 
of EP was obtained at each temperature studied for each individual sample type.  For the 
Ca-ATPase + phospholamban sample, the steady EP level was decreased approximately 
25% (0.06 ± 0.01 nmol EP / mg total protein) compared to the antibody-treated Ca-
ATPase + phospholamban sample (0.08 ± 0.02 nmol EP / mg total protein).  This 
phospholamban-dependent inhibition of Ca-ATPase EP level was similar to the effect of 
phospholamban on Ca-ATPase activity (Figure 5), and is consistent with previous studies 
of the effects of phospholamban on Ca-ATPase phosphorylation by ATP using insect cell 
microsome samples (Mahaney et al., 2000).  Thus, the individual values of steady-state 
EP levels measured at the three temperatures were averaged to provide one EP level for 
each sample type, which were used in subsequent calculations of Ca-ATPase turnover.  
When expressed alone, the Ca-ATPase steady-state EP level was 0.09 ± 0.02 nmol EP / 
mg total protein, which was similar to the steady-state EP level of the antibody-treated 
Ca-ATPase + phospholamban sample.   
 
Effect of Phospholamban on Ca-ATPase Activation Energy. 
  For each sample type studied, the ratio of Ca-ATPase activity (nmol ATP 
hydrolyzed per mg protein per second) to EP level (nmol 32P bound per mg total protein) 
was calculated to determine the temperature dependence of the Ca-ATPase turnover 
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number, kcat (s-1).  The turnover number data was analyzed by an Arrhenius plot (Figure 
7), and the slope (Ea/R, where R is the gas constant, 8.314 J per K per mole) of the plot 
provided the activation energy.  The Arrhenius plot derived from the Ca-ATPase only 
and Ca-ATPase + phospholamban samples each consisted of two linear phases, with the 
break occurring at 15oC, as has been documented previously (Bigelow et al., 1986).  Use 
of two linear phases as opposed to one single line was justified by least squares analysis, 
which showed that the correlation coefficients of the two phases was significantly better 
than the correlation coefficient of a single line for each sample type (see legend of Figure 
7).  From the slopes of the individual plots, it was apparent that the Ca-ATPase in the 
absence of phospholamban (Figure 7, top) had a smaller activation energy above 15oC 
(31 ± 3 J / mol) relative to that of the Ca-ATPase in the presence of phospholamban 
(Figure 4, bottom), which was 51 ± 5 J / mol.  Treatment of the Ca-ATPase + 
phospholamban sample with 2D12 (Figure 4, bottom) had no significant effect on Ca-
ATPase activation energy (52 ± 5 J / mol).  The finding that the activation energy of the 
antibody-treated Ca-ATPase + phospholamban  sample was significantly different than 
the Ca-ATPase only sample was surprising in light of the activity and EP level 
experiments, which showed that the 2D12 antibody completely relieved Ca-ATPase 
inhibition by phospholamban. 
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Figure 7: Effect of phospholamban on the temperature dependence of Ca-ATPase 
turnover number (kcat).  The temperature-dependent Ca-ATPase turnover number at 
[Ca2+]free = 270 nM in the absence of phospholamban (Ca-ATPase Only, top panel) and in 
the presence of phospholamban (Ca-ATPase + PLB, bottom panel), was calculated from 
the activity data shown in Figure 6 and the catalytic site density of each sample type 
(described in the text).  The symbols and sample conditions correspond to those defined 
in Figure 5.  When plotted as shown in the figure (an Arrhenius plot), the slope 
coresponds to  Ea / R, where Ea is the activation energy and R is the gas constant.  For 
each sample type, the plot consisted of two distinct and well-resolved phases with a break 
at 15 oC.  This was confirmed by least-squares analysis, which showed a significantly 
better correlation coefficient ( r ) for individual fits between 5-15 oC and 15-40 oC  as 
opposed to one single fit from 5-40 oC.  The activation energies derived from the plots 
were: Ca-ATPase only, 13 ± 2 J/mol between 5-15 oC (r = 0.98) and 31 ± 3 J/mol 
between 15-40 oC (r = 0.991); untreated Ca-ATPase + phospholamban, 9 ± 1 J/mol 
between 5-15 oC (r = 0.75) and 51 ± 5 between 15-40oC (r = 0.99); and antibody-treated 
Ca-ATPase + phospholamban, 15 ± 2 J/mol between 5-15 oC (r = 0.93) and 52 ± 5 J/mol 
between 15-40 oC (r = 0.99). 
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Chapter 4: Discussion 
 
Overview.   
The purpose of this study was to test the hypothesis that phospholamban inhibits 
Ca-ATPase by increasing the activation energy required for enzyme turnover.  To test 
this hypothesis, we conducted an Arrhenius analysis of the Ca-ATPase turnover number 
to determine Ca-ATPase activation energy in the absence and presence of 
phospholamban.  The effect of phospholamban on the Ca-ATPase was further explored 
using a monoclonal antibody, 2D12, against phospholamban, which is known to relieve 
phospholamban inhibition of the Ca-ATPase similar to phospholamban phosphorylation.  
The results indicated that Ca-ATPase activation energy was significantly higher when 
phospholamban was present compared to that when phospholamban was absent.  
Surprisingly, there was no significant difference in Ca-ATPase activation energy for Ca-
ATPase + phospholamban samples treated with anti-phospholamban antibody versus 
those that were not treated, despite a significant increase in steady state Ca-ATPase 
activity following treatment with the antibody.   
 
The Baculovirus-insect Cell Ca-ATPase / Phospholamban Expression System.  
The samples used in this study were prepared using the baculovirus-High Five 
insect cell (fall army worm fibroblast) expression system for the Ca-ATPase and 
phospholamban.  The advantage of using an expression system rather than native cardiac 
sarcoplasmic reticulum (SR) vesicles was the ability to study Ca-ATPase activation 
energy in the absence and presence of phospholamban. Because phospholamban is an 
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endogenous integral membrane protein in cardiac SR, it is not possible to remove it from 
the membrane without the use of strong detergents or reagents that would change the 
fundamental physical properties of the membrane.  The High Five cell expression system 
was based on a similar system using Sf21 insect cells (fall army worm ovarian cells), 
which was developed and characterized by Autry and Jones (1997) and in more detail by 
Mahaney et al. (2000).  The High Five cells produced a greater amount of expressed Ca-
ATPase (and phospholamban) per mg of total protein, with better specific Ca-ATPase 
activity compared to protein expressed by the Sf21 cells.  Thus, a single preparation of 
expressed protein provided sufficient material for a complete set of experiments, and the 
kinetics data obtained in each experimental set was of sufficient quality to allow for 
reproducibility even under the most stringent experimental conditions.  The Mahaney 
laboratory and collaborators (manuscript in preparation) have characterized the physical 
and kinetic properties of the expressed Ca-ATPase, which were found to be nearly 
identical to the kinetic properties of the Ca-ATPase in native cardiac SR vesicles.  Thus 
the High Five cell Ca-ATPase and phospholamban expression system was a valid model 
for studying the physical and kinetic mechanism by which phospholamban regulates the 
Ca-ATPase. 
 
Ca-ATPase Turnover Number.  
 For this study, Ca-ATPase turnover was defined as the steady-state ATPase 
activity of the enzyme (nmoles ATP split per mg total protein per second) normalized to 
the catalytic site density of the enzyme in the samples (nmol EP per mg total protein).  
The resulting turnover number, kcat, had units of sec-1.  A simpler analysis using only the 
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temperature-dependent enzyme velocity would have sufficed for this study.  As such, one 
could normalize the Ca-ATPase activity of a given sample to the amount of expressed 
enzyme within that sample to facilitate the direct comparison of two different expressed 
samples.  However, Mahaney et al. (2000) showed that despite nearly equal amounts of 
Ca-ATPase (per wt basis) in the insect cell microsome preps, Ca-ATPase in the presence 
of phospholamban has markedly lower steady-state activity than microsomes containing 
Ca-ATPase alone, even under experimental conditions that uncouple phospholamban 
from the Ca-ATPase (e.g., high [Ca2+], anti-phospholamban antibody, phospholamban 
phosphorylation).  Thus, the catalytic site density (steady-state phosphoenzyme formed) 
was an important factor to consider to understand the effect of phospholamban on the 
amount of kinetically competent Ca-ATPase in each sample type.  
 
Effect of Phospholamban on Ca-ATPase Activation Energy.  
 The results of these experiments indicated that the presence of phospholamban 
increased Ca-ATPase activation energy by 167%, from 31 ± 3 J/mol (Ca-ATPase only) to 
52 ± 5 J/mol (Ca-ATPase + phospholamban).  However the mechanistic basis of this 
effect is not yet clear.  The Ca-ATPase enzyme cycle consists of a number of partial 
reactions, some of which are quite sensitive to the environmental conditions.  Most 
notably, Froehlich and Taylor (1976) and Froehlich and Heller (1985) have shown that 
the three slowest steps in the enzyme cycle are calcium release from E2P, E2P·Ca2, and 
phosphoenzyme hydrolysis, E2P to E2 + Pi, and the E2 to E1 transition.  Because the 
rates of these transitions are all similar and highly interdependent, it is generally accepted 
that the rate of enzyme turnover is determined by the combination of the rates of these 
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steps.  Furthermore, the rate each of these steps is dependent on pH, [Ca2+], [ATP] and 
temperature.  Because [Ca2+] and pH were buffered, temperature was the only variable 
that changed significantly in these experiments.  Nevertheless, temperature has 
significant effects on the relative rates of these three steps, and thereby changes which of 
the three steps is dominant for rate limitation for overall enzyme turnover.  Thus, while 
we found that the presence of phospholamban changed the activation energy of the Ca-
ATPase, we cannot be certain whether one single step changed or a combination of steps 
within a series of reactions changed in response to phospholamban.  The solution for this 
problem is to study the effect of phospholamban on the temperature dependence of each 
of the partial reactions in the Ca-ATPase cycle independently.  This would show how 
phospholamban affects the activation energy of each individual step in the enzyme cycle, 
which in turn would reveal the mechanistic basis by which phospholamban inhibits Ca-
ATPase steady-state turnover. 
Based on the effect of phospholamban on the [Ca2+]-dependence of Ca-ATPase 
activity (Figure 5), it is clear that phospholamban is a negative allosteric modulator of 
Ca-ATPase.  Using this model, the Ca-ATPase would have two fundamental forms in 
equilibrium: a tense (or T) state, characterized as being less active with a decreased 
affinity for substrate (i.e., Ca2+) and a relaxed (or R) state, having greater activity and a 
higher substrate affinity (Figure 8).  In the presence of phospholamban, the enzyme has 
decreased activity and a lower apparent Ca2+ affinity, indicating that phospholamban 
shifts the T to R equilibrium toward the T state, typical of a negative allosteric modulator.   
Because negative allosteric modulators are reversible inhibitors of enzymes, the presence 
of substrate at high enough levels can shift the T to R equilibrium back toward the R  
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Figure 8:  Phospholamban as a negative allosteric modulator of Ca-ATPase.  The 
Ca-ATPase exists in two fundamental forms.  The E1 state has high affinity for Ca2+ 
whereas the E2 state has low affinity for Ca2+.  As such, the E1 form of the enzyme is 
considered the relaxed form ( R ), which readily binds 2 Ca2+ ions cooperatively.  
Conversely, the E2 form is considered the tense form ( T ), which must first undergo a 
structural transition to R before Ca2+ can bind to the enzyme.  Work in the Mahaney 
laboratory (unpublished results) has shown that phospholamban increases the E2 
character of the enzyme, thus increasing the fraction of Ca-ATPase in the T form.  
However, increasing [Ca2+]free reverses this effect and saturating  [Ca2+]free completely 
overcomes the effect of phospholamban on the Ca-ATPase.  This behavior is consistent 
with phospholamban acting as a negative allosteric modulator of the Ca-ATPase.
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state, effectively reversing the effects of the modulator.  This is true for the effect of 
phospholamban on Ca-ATPase activity.  At high [Ca2+], there is essentially no difference 
in the Ca-ATPase Vmax in the presence or absence of phospholamban. 
Using a combination of rapid mixing kinetics techniques and time-resolved 
electron paramagnetic resonance spectroscopy, Mahaney et al. (1995) showed that Ca-
ATPase oligomeric interactions are important for high affinity Ca2+ binding and 
activation of ATP-dependent phosphoenzyme formation.  Subsequently, Mahaney et al. 
(unpublished results) showed that during steady-state enzyme cycling, the Ca-ATPase 
operates as a tetrameric complex.  At any given time, the four subunits within the 
tetramer correspond to the principal intermediates in the Ca-ATPase cycle: two E1 units 
(Ca2·E1·ATP and E1P) and two E2 units (E2P and E2).  By modulating the reaction 
conditions, the authors showed that the distribution of E1 and E2 states could be shifted 
more towards E2, with a net decrease in apparent Ca2+ affinity, or toward E1, with a net 
increase in apparent Ca2+ affinity.  Therefore, the Ca-ATPase T state is defined as an 
oligomeric complex with more E2 units, whereas the Ca-ATPase R state is an oligomeric 
complex with more E1 units.  Both studies showed that the activation of T to R was rate 
limiting for enzymatic cycling.   
Recent studies in the Mahaney laboratory have focused on the effect of 
phospholamban on Ca-ATPase oligomeric interactions using a variety of kinetic and 
spectroscopic approaches.  Southall et al. (2001) used saturation transfer EPR to show 
that the presence of phospholamban results in a spatial reorientation of Ca-ATPase 
subunits within a Ca-ATPase oligomer relative to Ca-ATPase in the absence of 
phospholamban.  Mahaney and coworkers (2002) using rapid mixing kinetics, and 
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Waggoner et al. (2001) using fluorescence spectroscopy, showed that in the presence 
phospholamban, the Ca-ATPase had an increased E2 character relative to Ca-ATPase in 
the absence of phospholamban.  The results of these studies suggest that phospholamban 
shifts the Ca-ATPase T to R equilibrium toward the T state.   
Mahaney et al. (1995 and unpublished results) showed that the interconversion of 
Ca-ATPase oligomeric units from the less active (T state) to more active (R state) 
configuration was rate-limiting for the initiation of the enzyme cycle.  Therefore, we 
propose that the activation energy measured in the present study corresponds to the 
energy required for the physical conversion of Ca-ATPase from the T to the R state 
preceding high affinity Ca2+ binding and ATP-dependent enzyme phosphorylation during 
the steady state.  Because phospholamban shifts the T to R equilibrium more strongly 
toward the T state, greater energy is required for the activation of T to R in the presence 
of phospholamban than in the absence of phospholamban.  A key test of this proposal 
would be to conduct the activation energy studies at a saturating [Ca2+], where 
phospholamban is effectively uncoupled from the Ca-ATPase (e.g., [Ca2+] > 1 µM; 
Figure 2). Under these conditions, one would expect no phospholamban-dependent 
change in Ca-ATPase activation energy.  
 
Anti-phospholamban Antibody Had No Effect on Ca-ATPase Activation Energy.   
One aspect of the study that is difficult to account for is the lack of an effect on 
Ca-ATPase activation energy when the Ca-ATPase + phospholamban samples were 
treated with anti-phospholamban antibody (Figure 7).  We found that treatment of the Ca-
ATPase + phospholamban samples with anti-phospholamban antibody did not result in a 
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decrease in Ca-ATPase activation energy to a value similar to that observed for the Ca-
ATPase alone.  This lack of change was not due to a failure of the antibody to uncouple 
phospholamban from the Ca-ATPase.  A sufficient amount of antibody was used to 
maximize the stimulatory effects of uncoupling phospholamban, based on previous 
antibody titration experiments (Autry and Jones, 1997; Mahaney et al., 2000).  As shown 
in Figure 3, treatment of the Ca-ATPase + phospholamban with the anti-phospholamban 
antibody resulted in a 20% stimulation of Ca-ATPase activity at 270 nM [Ca2+]free, 
confirming the stimulatory effects of uncoupling phospholamban from the Ca-ATPase.  
Likewise, we found that antibody treatment stimulated Ca-ATPase EP formation by 
about 25%, which was a similar increase as that observed for Ca-ATPase activity 
following antibody treatment.  These trends were similar over most of the temperature 
range studied.  Because turnover is defined as the ratio of Ca-ATPase velocity to EP 
level, and phospholamban decreased both kinetic parameters by a similar amount, the 
resultant Ca-ATPase activation energy did not change significantly following antibody 
treatment.  
One possible interpretation of this result is that phospholamban may decrease Ca-
ATPase activity by completely inhibiting a fraction of enzyme, leaving the remaining 
enzyme fully active, rather than by inhibiting partially all the enzyme units.  That is to 
say, because Ca-ATPase activity = kcat x [E]T, a phospholamban-dependent decrease in 
the effective enzyme concentration would reduce enzyme activity without changing the 
turnover number (or presumably the temperature dependence of the turnover).  It is well 
documented (see Chapter 1, Introduction) that phospholamban exists in equilibrium 
between active monomers and inactive pentameric forms.  Thus, even at a molar 
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stoichiometry of one to two phospholamban per one Ca-ATPase, one would expect only a 
fraction of Ca-ATPase to have bound phospholamban.  This is consistent with 
phospholamban acting as a negative allosteric modulator of Ca-ATPase.  While the R to 
T equilibrium is shifted toward the inactive T state, the remaining R state is completely 
active.  As outlined above, a way to test this proposal would be to repeat the activation 
energy experiments at saturating [Ca2+]free, where phospholamban has essentially no 
effect on Ca-ATPase activity (Figure 2) or Ca-ATPase EP level (Mahaney et al., 2000). 
An outstanding question which remains is why the activation energy measured for 
Ca-ATPase expressed alone was so different from that measured for the antibody-treated 
Ca-ATPase + phospholamban sample.  It is possible that there was a fundamental 
difference in the physical environment of the Ca-ATPase in the absence and presence of 
phospholamban, that may have affected the thermodynamic or kinetic properties of the 
enzyme.  However, this is unlikely because kinetics studies (Froehlich et al., 2002) and 
spectroscopic studies (Waggoner et al., 2001; Southall et al., 2001) using nearly identical 
samples have shown that the two sample types are highly similar in terms of physical and 
kinetics properties.  Alternatively, it is possible that the thermodynamic and kinetics 
properties of the Ca-ATPase were fundamentally different in the absence of 
phospholamban than in the presence of phospholamban, even when phospholamban was 
physically uncoupled from the Ca-ATPase following antibody treatment.  This seems 
unlikely, however, because the [Ca2+]-dependence of Ca-ATPase activity for the Ca-
ATPase in the presence of phospholamban treated with antibody was nearly identical to 
that of the Ca-ATPase alone (Figure 5).  Clearly additional studies comparing the Ca-
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ATPase only and the antibody-treated Ca-ATPase + phospholamban sample are needed 
to understand this lack of effect.   
 
Future directions:  The studies of this project have provided good evidence that 
phospholamban increases the activation energy of the Ca-ATPase.  More detailed studies 
directed at understanding the effect of phospholamban on individual reactions in the Ca-
ATPase cycle will help elucidate the mechanistic and thermodynamic bases by which 
phospholamban inhibits Ca-ATPase activity.  
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